Ovid Therapeutics (OVID) Research & Development (2016 - 2026)
Ovid Therapeutics (OVID) posted Research & Development of $11.2 million for Q1 2026, up 69.69% on a QoQ basis from $6.6 million in Q4 2025, and up 67.91% year-over-year from $6.7 million in Q1 2025.
Ovid Therapeutics (OVID) Research & Development (2016 - 2026) Analysis & Trends
Ovid Therapeutics' Research & Development history runs 11 years deep, the most recent figure standing at $11.2 million for Q1 2026.
- Quarterly Research & Development rose 67.91% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.1 million (down 8.83% YoY) and the FY2025 annual result came in at $25.6 million, down 30.42% from the prior year.
- Research & Development was $11.2 million for Q1 2026 at Ovid Therapeutics, up from $6.6 million in the prior quarter.
- Across five years, Research & Development topped out at $12.6 million in Q2 2024 and bottomed at $5.2 million in Q3 2022.
- A 5-year average of $7.5 million and a median of $6.6 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development tumbled 54.83% — and 2024, when it surged 109.73%.
- Ovid Therapeutics' Research & Development stood at $5.6 million in 2022, then surged by 91.53% to $10.6 million in 2023, then sank by 44.34% to $5.9 million in 2024, then advanced by 11.24% to $6.6 million in 2025, then surged by 69.69% to $11.2 million in 2026.
- Business Quant data shows OVID's Research & Development at $11.2 million in Q1 2026, $6.6 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 343.97 Mn |
| 10 | Ovid Therapeutics | 118.66 Mn | -36.86 Mn | - | 11.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.18 Mn |
| Dec 31, 2025 | 6.59 Mn |
| Sep 30, 2025 | 5.87 Mn |
| Jun 30, 2025 | 6.47 Mn |
| Mar 31, 2025 | 6.66 Mn |
| Dec 31, 2024 | 5.92 Mn |
| Sep 30, 2024 | 7.86 Mn |
| Jun 30, 2024 | 12.58 Mn |
| Mar 31, 2024 | 10.40 Mn |
| Dec 31, 2023 | 10.64 Mn |
| Sep 30, 2023 | 5.33 Mn |
| Jun 30, 2023 | 6.00 Mn |
| Mar 31, 2023 | 6.62 Mn |
| Dec 31, 2022 | 5.56 Mn |
| Sep 30, 2022 | 5.18 Mn |
| Jun 30, 2022 | 6.05 Mn |
| Mar 31, 2022 | 7.83 Mn |
| Dec 31, 2021 | 12.30 Mn |
| Sep 30, 2021 | 4.92 Mn |
| Jun 30, 2021 | 7.68 Mn |